Head, Neck Cancer’s Global Challenge

Head, Neck Cancer’s Global Challenge July 26, 2016 Head and neck cancer is a growing challenge with more than 650,000 new cases and more than 360,000 deaths worldwide each year. Historically, the death rate associated with this cancer is particularly high due to late-stage diagnosis and intervention. More than 40 percent of those diagnosed with

Vigilant Biosciences Announces Oral Presentation on CD44 and Associated Markers in Oral Rinses and Tissues from Oral Cancer Patients at AHNS 9th International Conference on Head and Neck Cancer

Vigilant Biosciences Announces Oral Presentation on CD44 and Associated Markers in Oral Rinses and Tissues from Oral Cancer Patients at AHNS 9th International Conference on Head and Neck Cancer July 13, 2016 FORT LAUDERDALE, Florida and SEATTLE Vigilant Biosciences, Inc., a leading innovator and developer of solutions that aid in the early detection and intervention

Fort Lauderdale-based Vigilant Biosciences Raises $5 Million for Oral Cancer Detection Products

Fort Lauderdale-based Vigilant Biosciences Raises $5 Million for Oral Cancer Detection Products July 12, 2016 Fort Lauderdale startup Vigilant Biosciences has raised $5 million from investors, bringing its total amount raised to $12.5 million to date, the company said Monday. The money will be used for commercial development of the company’s OncAlert oral cancer detection

Vigilant Biosciences Raises $5 Million Second Round Series B Financing

Vigilant Biosciences Raises $5 Million Second Round Series B Financing July 11, 2016 FORT LAUDERDALE, Florida Vigilant Biosciences, Inc. (“Vigilant”), a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, today announced the successful completion of a $5 million round of financing through its Series B2 offering, bringing

Life Sciences Company Taking Oral Cancer Detection Products to Market

Life Sciences Company Taking Oral Cancer Detection Products to Market July 11, 2016 Vigilant Biosciences is developing products for the early detection and intervention of cancer. On Monday, the Fort Lauderdale life sciences company announced it closed a $5 million round of financing, bringing its total amount of funding raised to date to $12.5 million. Existing

Vigilant Biosciences Raises $10.5M in Series B Round

Vigilant Biosciences Raises $10.5M in Series B Round July 11, 2016 Vigilant Biosciences, an oral cancer testing company, announced that it has raised a total of $10.5 million in Series B financing. The second phase of the Series B round brought in $5 million and investors in this phase included White Owl Capital Partners, venVelo

Vigilant Raises $5M to Commercialize Oral Cancer Test

Vigilant Raises $5M to Commercialize Oral Cancer Test July 11, 2016 Vigilant Biosciences has raised $5 million to commercialize OncAlert, its oral cancer detection test. Vigilant has received $12.5 million in total funding, including most recently a round of $5 million in Series B funding. The proceeds will be used for the international commercialization of

© 2020 Vigilant Biosciences

Follow Us

3900001 Rev2